Last reviewed · How we verify
PTC+Pertuzumab
PTC+Pertuzumab combines a PTC (likely a protein tyrosine kinase inhibitor or similar agent) with pertuzumab, a HER2-targeting monoclonal antibody that blocks HER2 dimerization to inhibit tumor growth.
PTC+Pertuzumab combines a PTC (likely a protein tyrosine kinase inhibitor or similar agent) with pertuzumab, a HER2-targeting monoclonal antibody that blocks HER2 dimerization to inhibit tumor growth. Used for HER2-positive breast cancer (phase 3).
At a glance
| Generic name | PTC+Pertuzumab |
|---|---|
| Also known as | Paclitaxel; 80 mg/m2; day 1,8, Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1, Carboplatin; AUC=6; day 1, Pertuzumab; 420 mg (loading dose 840 mg); day 1 |
| Sponsor | The Netherlands Cancer Institute |
| Drug class | Monoclonal antibody + investigational agent combination |
| Target | HER2 (pertuzumab component); PTC target unknown |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pertuzumab is a humanized monoclonal antibody that binds to HER2 and prevents its heterodimerization with other HER family receptors, blocking downstream signaling. The combination with PTC (the specific agent is not clearly defined in available literature) likely aims to provide complementary HER2-pathway inhibition or target additional oncogenic pathways in HER2-positive tumors.
Approved indications
- HER2-positive breast cancer (phase 3)
Common side effects
- Cardiotoxicity
- Infusion reactions
- Diarrhea
- Nausea
Key clinical trials
- Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study (PHASE2)
- Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (PHASE3)
- Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PTC+Pertuzumab CI brief — competitive landscape report
- PTC+Pertuzumab updates RSS · CI watch RSS
- The Netherlands Cancer Institute portfolio CI